| Literature DB >> 34223086 |
Obed Kwabena Offe Amponsah1, Kwame Ohene Buabeng1, Alex Owusu-Ofori2,3, Nana Kwame Ayisi-Boateng3,4, Katri Hämeen-Anttila5, Hannes Enlund5.
Abstract
BACKGROUND: Actionable data on antimicrobial use is important when planning strategic interventions such as antimicrobial stewardship to address the challenge of drug resistance, particularly in resource-constrained settings.Entities:
Year: 2021 PMID: 34223086 PMCID: PMC8210176 DOI: 10.1093/jacamr/dlab008
Source DB: PubMed Journal: JAC Antimicrob Resist ISSN: 2632-1823
Patient inclusion and exclusion criteria for point prevalence survey
| Level | Inclusion | Exclusion |
|---|---|---|
| Ward | All acute care inpatient wards in the hospitals. | Long-term care wards, Emergency departments (except for wards attached to be monitored for more than 24 h), Day surgery and Day care wards. |
| Patients | Hospitalized patient already admitted in the ward as at 08:00 am on day of survey whether receiving antibiotic treatment or not. | Patients admitted after 08:00 am on day of survey, all Day care patients. |
| Antibiotics | Only antibiotics included in ANNEX XI of the WHO protocol administered by oral, parenteral, rectal or inhalation routes were included, antibiotic initiated by 08:00 am on survey day. | Topical antibiotics, antibiotic started after 08:00 am on day of survey. |
Demographics and prevalence of antibiotic use by hospital
| Factor |
| |||
|---|---|---|---|---|
| Overall ( | UHS ( | APH ( | EGH ( | |
| Gender | ||||
| Female | 120 (63.2%) | 29 (65.9%) | 60 (59.4%) | 31 (68.9%) |
| Male | 63 (33.2%) | 13 (29.6%) | 36 (35.6%) | 14 (31.1%) |
| Age | ||||
| ≥2 years ( | 30 (21–48) | 27.5 (21.0–42.0) | 35.0 (20.0–57.0) | 29.0 (21.0–44.0) |
| 0–23 months ( | 0.13 (0.06–0.30) | 0.03 (0.03–0.13) | 0.2 (0.1–0.3) | 0 (0.0–7.0) |
| Patients on antibiotics | 115 (60.5%) | 68 (67.3%) | 24 (54.5%) | 23 (51.1%) |
| Number of antibiotics per patient ( | ||||
| 1 | 37 (32.2%) | 26 (38.2%) | 4 (16.7%) | 7 (30.4%) |
| 2 | 68 (59.1%) | 34 (50.0%) | 19 (79.2%) | 15 (65.2%) |
| 3 | 10 (8.7%) | 1 (4.2%) | 1 (4.4%) | |
N=Total number of patients; n=number of patients.
Summary of antibiotic indication
| Hospital | ||||
|---|---|---|---|---|
| Factor ( | Total | UHS | APH | EGH |
| Indication type | ||||
| Community-acquired infection | 42 (36.5%) | 10 (41.7%) | 21 (30.9%) | 11 (47.8%) |
| Surgical prophylaxis | 30 (26.1%) | 9 (37.5%) | 17 (25.0%) | 4 (17.4%) |
| Hospital-acquired infection | 18 (15.7%) | 1 (4.2%) | 15 (22.1%) | 2 (8.7%) |
| Medical prophylaxis | 16 (13.9%) | 3 (12.5%) | 7 (10.3%) | 6 (26.1%) |
| Other | 9 (7.8%) | 1 (4.2%) | 8 (11.8%) | 0 (0.0%) |
| Reason for antibiotic use in notes? | ||||
| Yes | 89 (88.1%) | 23 (95.8%) | 44 (80.0%) | 22 (100.0%) |
| Culture sample taken? | ||||
| Yes | 3 (2.7%) | 2 (8.3%) | 0 (0.0%) | 1 (4.6%) |
Results shown are n (%).
Antibiotics given to prevent bacterial infections in susceptible groups, such as patients with Crohn’s disease, pregnant women with suspected/susceptible to preterm/premature rupture of membranes to prevent early-onset neonatal Group B streptococcal disease.
Figure 1.Prescribed antibiotics by antibiotic classes.
Prescribed antibiotics by hospital
| Hospital | ||||
|---|---|---|---|---|
| Antibiotic | Overall | UHS | APH | EGH |
| Amoxicillin ( | 42 (36.5%) | 12 (50.0%) | 18 (26.5%) | 12 (52.2%) |
| Ciprofloxacin ( | 20 (17.4%) | 3 (12.5%) | 15 (22.1%) | 2 (8.7%) |
| Ceftriaxone ( | 13 (11.3%) | 2 (8.3%) | 11 (16.2%) | 0 (0.0) |
| Cefuroxime ( | 11 (9.6%) | 3 (12.5%) | 6 (8.8%) | 2 (8.7%) |
| Ampicillin ( | 9 (7.8%) | 0 (0.0) | 9 (26.5%) | 0 (0.0) |
| Clindamycin ( | 5 (4.4%) | 0 (0.0) | 3 (4.4%) | 2 (8.7%) |
| Benzylpenicillin ( | 3 (2.6%) | 0 (0.0) | 1 (1.5%) | 2 (8.7%) |
| Amikacin ( | 2 (1.7%) | 0 (0.0) | 0 (0.0) | 2 (8.7%) |
| Cefotaxime ( | 2 (1.7%) | 0 (0.0) | 2 (2.9%) | 0 (0.0) |
| Flucloxacillin ( | 2 (1.7%) | 0 (0.0) | 2 (2.9%) | 0 (0.0) |
| Metronidazole ( | 2 (1.7%) | 0(0.0) | 1 (1.5%) | 1 (4.4%) |
| Azithromycin ( | 1 (0.9%) | 1 (4.2%) | 0 (0.0) | 0 (0.0) |
| Cefpodoxime ( | 1 (0.9%) | 1 (4.2%) | 0 (0.0) | 0 (0.0) |
| Erythromycin ( | 1 (0.9%) | 1 (4.2%) | 0 (0.0) | 0 (0.0) |
| Gentamicin ( | 1 (0.9%) | 1 (4.2%) | 0 (0.0) | 0 (0.0) |
Results shown are n (%).
WHO AWaRe classification: A, Access (46.7%); W, Watch (40%); Re, Reserve (0); U, Unclassified (13.3%).
Antibiotic names are the International Nonproprietary Name (INN).
Patient variables and association with antibiotic use
| Patients on antibiotics, | |||
|---|---|---|---|
| Variable | No | Yes |
|
| Surgery on admission | |||
| Yes | 5 (13.9%) | 31 (86.1%) | 0.001 |
| Type of surgery | |||
| Minimal | 0 (0.0%) | 4 (100.0%) | |
| NHSN | 1(5.6%) | 17 (94.4%) | 1.000 |
| McCabe score | |||
| Non-Fatal | 62 (37.6%) | 103 (62.4%) | |
| Rapidly Fatal | 10 (52.6%) | 9 (47.4%) | 0.386 |
| Ultimately Fatal | 3 (50.0%) | 3 (50.0%) | |
| Urinary catheter | |||
| Yes | 6 (18.8%) | 26 (81.3%) | |
| Peripheral Vascular Catheter | |||
| Yes | 38 (29.9%) | 89 (70.1%) | <0.001 |
NHSN, National Healthcare Safety Network surgery list defined in Annex IX of WHO protocol.
Chi-squared test was performed.
Fisher’s exact test.
Logistic regression to adjust variables for potential confounders (all facilities)
| Variable | UAOR (95% CI) | AOR (95% CI) |
|
|---|---|---|---|
| Patients on antibiotics | |||
| Age in years | 1.00 (0.98–1.01) | 0.98 (0.96–1.00) | 0.022 |
| Gender | |||
| Female | 1 | 1 | |
| Male | 0.65 (0.35–1.21) | 2.33 (0.88–6.20) | 0.09 |
| Surgery on Admission | |||
| No | 1 | 1 | |
| Yes | 5.1 (1.89–14.00) | 3.2 (0.83–12.56) | 0.092 |
| Comorbidities | |||
| McCabe Score | |||
| Rapidly Fatal | 1 | 1 | |
| Non-Fatal | 1.8 (0.71–4.79) | 2.51 (0.60–10.49) | 0.206 |
| Ultimately Fatal | 1.1 (0.18–6.97) | 0.60 (0.04–9.83) | 0.721 |
| Use of catheter | |||
| No | 1 | 1 | |
| Yes | 3.5 (1.38–9.11) | 4.26 (0.82–22.02) | 0.084 |
| Type of infection | |||
| Malaria | |||
| No | 1 | 1 | |
| Yes | 0.4 (0.19–0.98) | 0.33 (0.11–0.94) | 0.038 |
| Tuberculosis | |||
| No | 1 | ||
| Yes | 0.2 (0.01–2.02) | – | – |
| HIV | |||
| No | 1 | ||
| Yes | 1.5 (0.29–8.12) | – | – |
| Peripheral vascular catheter | |||
| No | 1 | 1 | |
| Yes | 3.5 (1.82–6.80) | 2.31 (0.90–5.87) | 0.08 |
UAOR, unadjusted odds ratio; AOR, adjusted odds ratio. Dashes represent variables that were dropped due to limited numbers and/or collinearity.